Evidence map›Paper›PMID 39060161›Full record

ReviewThe Journal of pharmacology and experimental therapeutics2024

Cannabis and Cannabinoid Signaling: Research Gaps and Opportunities.

Rita J Valentino, Nora D Volkow

Abstract readReview
In one paragraph

Review in The Journal of pharmacology and experimental therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Cannabinoids: Medicine or PoisonBalkan medical journal · 2025
    Article
  4. Article
  5. Real-Time Optical Control of CB1 Receptor SignalingJournal of the American Chemical Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rita J ValentinoNational Institute on Drug Abuse, North Bethesda, Maryland valentinorj@nida.nih.gov.
Nora D VolkowNational Institute on Drug Abuse, North Bethesda, Maryland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cannabis and its products have been used for centuries for both medicinal and recreational purposes. The recent widespread legalization of cannabis has vastly expanded its use in the United States across all demographics except for adolescents. Meanwhile, decades of research have advanced our knowledge of cannabis pharmacology and particularly of the endocannabinoid system with which the components of cannabis interact. This research has revealed multiple targets and approaches for manipulating the system for therapeutic use and to ameliorate cannabis toxicity or cannabis use disorder. Research has also led to new questions that underscore the potential risks of its widespread use, particularly the enduring consequences of exposure during critical windows of brain development or for consumption of large daily doses of cannabis with high content

Indexed as

CannabinoidsCannabisSignal TransductionAnimalsEndocannabinoidsEvidence GapsHumansReceptors, CannabinoidCannabinoidsEndocannabinoidsReceptors, Cannabinoid

Identifiers

PMID39060161
PMCPMC11493439

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.